A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection

Basit Öğe Kaydı
dc.contributor.authorCeylan, Bahadir
dc.contributor.authorMete, Bilgul
dc.contributor.authorFincanci, Muzaffer
dc.contributor.authorAslan, Turan
dc.contributor.authorAkkoyunlu, Yasemin
dc.contributor.authorOzgunes, Nail
dc.contributor.authorColak, Onur
dc.date.accessioned2024-04-24T16:01:55Z
dc.date.available2024-04-24T16:01:55Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe aimed to investigate whether mean platelet volume (MPV) and platelet distribution width (PDW) are variables determining the severity of liver fibrosis in patients with chronic HBV infection. Patients were divided into two groups with fibrosis scores of 0-2 and 3-6 (according to Ishac scoring system). Whether MPV and PDW were independent variables determining the severity of liver fibrosis score or not was investigated by comparing these groups. Of the 111 cases, 74 (66.7 %) were male (mean age 37.7 +/- 11.6 years). Twenty-two of the cases (19.8 %) were HBeAg-positive. Fibrosis scores of 42 cases (37.8 %) were a parts per thousand yenaEuro parts per thousand 3 and the remaining 69 cases had fibrosis scores < 3 (62.2 %). Independent variables determining the severity of fibrosis score were low levels of albumin and mean platelet volume, and high levels of prothrombin time and PDW (Odds ratio (95 % confidence interval) and p values were 0.105 (0.018-0.605) and 0.012 for albumin, 0.402 (0.234-0.692) and 0.001 for mean platelet volume, 1.529 (1.183-1.975) and 0.001 for PDW, and 0.924 (0.875-0.976) and 0.005 for prothrombin time, respectively). The sensitivity, specificity, positive predictive value and negative predictive value of regression model that is established using above mentioned parameters were 88.1, 75.3, 68.5, and 91.7 %, respectively (AUC = 0.886, p = 0.0001). MPV and PDW are independent variables determining the severity of liver fibrosis, and the regression model that is established using these parameters along with other markers, may give more information about the severity of liver fibrosis.en_US
dc.description.sponsorshipNovartis Pharmaceutical Company; Merck Pharmaceutical Companyen_US
dc.description.sponsorship(1) The presented data belong to Realist Observational Study. Realist Observational study is supported financially by Novartis Pharmaceutical Company. (2) Payment for English translation of the article was made by Merck Pharmaceutical Company.en_US
dc.identifier.doi10.1007/s00508-013-0394-3
dc.identifier.endpage460en_US
dc.identifier.issn0043-5325
dc.identifier.issn1613-7671
dc.identifier.issue15-16en_US
dc.identifier.pmid23860694
dc.identifier.scopus2-s2.0-84883358200
dc.identifier.scopusqualityQ1
dc.identifier.startpage453en_US
dc.identifier.urihttps://doi.org/10.1007/s00508-013-0394-3
dc.identifier.urihttps://hdl.handle.net/11468/14490
dc.identifier.volume125en_US
dc.identifier.wosWOS:000323670700005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofWiener Klinische Wochenschrift
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis B Virusen_US
dc.subjectLiver Fibrosisen_US
dc.subjectBlood Plateletsen_US
dc.titleA new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infectionen_US
dc.titleA new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu